Navigation Links
Actemra (tocilizumab) Third Phase III Study Results Show,Significant Improvement in Symptoms of Patients with Rheumatoid,Arthritis

- Multinational Phase III Study Meets Primary Endpoint in Rheumatoid Arthritis Patients Who Failed to Respond to Anti-tumor Necrosis Factor Treatments -

NUTLEY, N.J., July 10, 2007 /PRNewswire/ -- Roche today announced that results from the Actemra Radiate (RheumAtoiD ArthritIs Study in Anti-TNF FailurEs) trial successfully met its primary endpoint in patients with moderate to severe rheumatoid arthritis (RA) who failed to respond to anti-tumor necrosis factor treatments (anti-TNFs).

The trial - the third multinational Phase III study of ACTEMRA outside of Japan - showed that a greater proportion of patients treated with ACTEMRA plus methotrexate (4 mg/kg or 8 mg/kg) achieved a significant reduction in the signs and symptoms of RA as evaluated by ACR20 following 24 weeks of treatment, compared to those who were treated with placebo plus methotrexate.

ACTEMRA was generally well tolerated; the most common adverse events reported more frequently in the ACTEMRA arms of the RADIATE trial were nausea, headache, nasopharyngitis, diarrhea and upper respiratory tract infection.

"The study results reconfirm the findings from the previous multinational trials that interleukin-6 receptor inhibition is a novel mechanism for reducing inflammation caused by RA," said Lars Birgerson, M.D., Ph.D., Global Head Medical Affairs, Roche. "The data demonstrate that ACTEMRA can potentially offer an effective approach in reducing the signs and symptoms of RA, particularly when therapies such as anti-TNFs prove insufficient."

Data from this trial will be submitted for presentation at upcoming national scientific meetings. In addition, other Phase III trials exploring ACTEMRA in RA are ongoing with another study scheduled to report in 2007.

About the RADIATE Study

The RADIATE (RheumAtoiD ArthritIs Study in Anti-TNF FailurEs) study is a three-arm, randomized, double-blind, placebo-controlled study
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Actemra (tocilizumab) Significantly Improves Symptoms of Rheumatoid Arthritis Compared to a Current Standard of Care
2. Neurologix to Present at the Third Annual C.E. Unterberg Towbin Emerging Growth Conference
3. Lipitor Reduced the Risk of Coronary Events by Half and Stroke by Nearly One-Third in High-Risk Patients with Type 2 Diabetes Who Experienced a Recent Stroke
4. Can-Fite Proceeds with Development of Third Drug; Progress in Development of CF502 Will Be Presented at the Annual European Congress of Rheumatology
5. One-Third of Patients Discontinue Common Breast Cancer Therapy
6. CeNeRx BioPharma Announces Positive Phase I Results in First Human Trial of Third Generation RIMA Antidepressant
7. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
8. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
9. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone

Post Your Comments:
(Date:11/9/2009)...swire/ -- AMD LASERS just announced that industry ...accepted the position of Medical Director. In his...eeing research and development of new soft and har...or continuing education credits, authoring article... and lecturing and seminar engagements. ,, "We ...
(Date:11/9/2009)...Newswire/ -- Access MediQuip, LLC, the nation,s fi... medical device management solutions to the health...ng its corporate headquarters to Lake Mary, Florid...id growth, includes a major expansion of the Prime...January 2010 and relocation and expansion of the H...
(Date:11/9/2009)...RNewswire/ -- Thomson Reuters today announced th...a leading clinical surveillance solution that enab...-time and respond immediately to improve clinical ...This upgrade is available to current CareFocus cus...0 contains several powerful enhancements that impr...
Breaking Medicine Technology:AMD LASERS Names Dr. James Jesse as Medical Director 2Access MediQuip Moves Company Headquarters to Lake Mary, Florida 2Thomson Reuters Clinical Surveillance Solution Offers Powerful New Functionality to Improve Clinical Quality and Reduce Costs 2Thomson Reuters Clinical Surveillance Solution Offers Powerful New Functionality to Improve Clinical Quality and Reduce Costs 3Test Before Corneal Transplant May Improve Outcome 50548 1Test Before Corneal Transplant May Improve Outcome 50548 2Everock Inc Completes Reverse Merger with Privately Held All Natural Food Producer Natures Peak 50545 1Everock Inc Completes Reverse Merger with Privately Held All Natural Food Producer Natures Peak 50545 2Everock Inc Completes Reverse Merger with Privately Held All Natural Food Producer Natures Peak 50545 3Biocept Inc Announces Two New Director Appointments 12871 1Biocept Inc Announces Two New Director Appointments 12871 2
...WIRE)--May 23, 2007 - Synta,Pharmaceuticals Corp.,...d on discovering, developing, and commercializing ...tions, today announced,that survival and sub-popul...astatic melanoma of the Company,s lead oncology dr...nnual meeting of the,American Society of Clinical ...
...armaceutical Co, Ltd. Sponsored Study,Presented at...ng -, SAN DIEGO, May 23, 2007 /PRNewswire/ -- In a...with schizophrenia, the Otsuka,Pharmaceutical Co.,...tipsychotic aripiprazole demonstrated significant ...icacy endpoint, Positive and,Negative Syndrome Sca...
Other Medicine Technology:Synta Oncology Candidate STA-4783 Clinical Trial Results to Be,Presented at the ASCO Annual Meeting 2Synta Oncology Candidate STA-4783 Clinical Trial Results to Be,Presented at the ASCO Annual Meeting 3Investigational Study Evaluates the Effectiveness of Aripiprazole,in Adolescents With Schizophrenia 2Investigational Study Evaluates the Effectiveness of Aripiprazole,in Adolescents With Schizophrenia 3Investigational Study Evaluates the Effectiveness of Aripiprazole,in Adolescents With Schizophrenia 4Investigational Study Evaluates the Effectiveness of Aripiprazole,in Adolescents With Schizophrenia 5Investigational Study Evaluates the Effectiveness of Aripiprazole,in Adolescents With Schizophrenia 6Investigational Study Evaluates the Effectiveness of Aripiprazole,in Adolescents With Schizophrenia 7Investigational Study Evaluates the Effectiveness of Aripiprazole,in Adolescents With Schizophrenia 8Investigational Study Evaluates the Effectiveness of Aripiprazole,in Adolescents With Schizophrenia 9
(Date:11/9/2009)...e-USNewswire/ -- The American Academy of Physician...clinically practicing physician assistants (PAs) p...House of Representatives for passing Saturday its ... Health Care for America Act. ,, "We are especi...ly lower the cost of health care and greatly expan...
(Date:11/9/2009)...ital and the University of Florida Proton Therapy ...roton therapy for St. Jude patients. The announcem...dy to evaluate the use of proton therapy for rare .... , Under the clinical protocol, St. Jude will...F Proton Therapy Institute in Jacksonville, Fla. T...
(Date:11/9/2009)...hire plc (LSE: SHP, NASDAQ: SHPGY), the global spe...the availability of INTUNIV (guanfacine) Extended ...ates for the treatment of Attention-Deficit/Hypera...s ages 6 to 17. INTUNIV, a once-daily formulation... alpha-2A receptor agonist approved for the treatm...
(Date:11/9/2009)... first human embryonic stem cell treatment approve...estore limb function in rats with neck spinal cord...l trial to include people with cervical damage. ,...gave Geron Corp. of Menlo Park, Calif., permission...th thoracic spinal cord injuries, which occur belo...
(Date:11/9/2009)...ight be the reason why African Americans are not r...ate as similar patients in other racial groups. D... transplantation at Georgetown University Hospital...University Medical Center, and colleagues explore ...ican Journal of Transplantation . , Medicare co...
Breaking Medicine News(10 mins):Health News:American Academy of Physician Assistants Applauds U.S. House of Representatives for Passing Health Care Reform Bill 2Health News:St. Jude and UF Proton Therapy Institute to begin proton therapy clinical trial 2Health News:Once-daily INTUNIV (guanfacine) extended release tablets now available in US pharmacies 2Health News:Once-daily INTUNIV (guanfacine) extended release tablets now available in US pharmacies 3Health News:Once-daily INTUNIV (guanfacine) extended release tablets now available in US pharmacies 4Health News:UCI embryonic stem cell therapy restores walking ability in rats with neck injuries 2Health News:Physician bias might keep life-saving transplants from black and Hispanic patients 2
...nity,Hospital (Mission) will hold a major fundrais...ts emergency room, which treats an average of 16,0...of patients it was,originally designed to serve wh...asino-style,entertainment from 6 p.m. to 11 p.m. a...
...he Tower,ENT Group at Cedars Sinai Medical Center ...resenting a medical breakthrough on snoring at the...ention Center from May,15-17, 2008. Dr. Grossan wi...online.com/ ), Known as the pioneer of nasal irri...
...e cross hairs of radiation or chemotherapy may be ...echanisms are jammed, say University of Florida sc...l Cell. , Scientists studying fruit fly cells dis...e the cells to become naturally resistant to X-ray...
...on recognized several distinguished volunteers and...he Cure on the Hill Awards Luncheon" and,"Gold Hea...iation presented its Gold Heart Award to Coletta C...hest,volunteer honor, recognizing distinguished se...
...Denzel Washington will present two research schola...in Denzels hometown of Mount Vernon, N.Y. The cere...zel Washington Family Scholar in Neuroscience Awar... monthly support for a graduate-level researcher a...
...efits in Bamberg, Calhoun, Chester, Kershaw, Lanc... York Counties, INDIA...ueShield of South Carolina and WellPoint Inc. (NYS...s in 10 counties in South,Carolina. Plan benefits ...
Other Medicine News:Health News:Mission Community Hospital Hosts Spring Fundraiser to Refurbish Treasured Valley Emergency Room 2Health News:Renowned ENT Specialist, Dr. Murray Grossan, Announces Medical Breakthrough on Snoring at PRI-MED Convention in Anaheim on May 15-17 2Health News:'Destruct' triggers may be jammed in tumor cells, UF geneticists say 2Health News:Association Honors Top Volunteers, Staff Member at Washington, D.C. Meeting 2Health News:Association Honors Top Volunteers, Staff Member at Washington, D.C. Meeting 3Health News:Denzel Washington's hometown hosts awarding of scholarships bearing Washington family name 2Health News:Denzel Washington's hometown hosts awarding of scholarships bearing Washington family name 3Health News:BlueCross BlueShield of South Carolina and WellPoint Affiliate Receive State Approval for Ten South Carolina Counties 2Health News:BlueCross BlueShield of South Carolina and WellPoint Affiliate Receive State Approval for Ten South Carolina Counties 3
CHECK-FLO Performer Introducer Sets For Radial Artery Access
Extra Large Check-Flo Introducers
KELLER-TIMMERMANS INTRODUCER SETS
SHUTTLE-SL FLEXOR TUOHY-BORST Side-Arm Introducer Sets
Medicine Products: